P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy

Leukemia

Volumn 14, Issue 6, 2000, Pages 1018-1024

  Broxterman, H J ^a   Sonneveld, P ^b   Van Putten, W J L ^b   Lankelma, J ^a   Eekman, C A ^a   Ossenkoppele, G J ^b   Pinedo, H M ^a   Lowenberg B ^b   Schuurhuis, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Idarubicin; LRP; Major vault protein; P glycoprotein

Indexed keywords

AMSACRINE; ANTHRACYCLINE; CARRIER PROTEIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; LUNG RESISTANCE PROTEIN; MITOXANTRONE; MONOCLONAL ANTIBODY MRK 16; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RHODAMINE 123; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0034043234     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401796     Document Type: Article

References (39)

1. Bradley G, luranka PF, Ling V. Mechanisms of multidrug resistance. Biochem Biophys Acta 1988; 948: 87-128.
2. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer 1990; 45: 263-268.
3. Ino T, Miyazaki H, Isogai M, Nomura T, Tsuzuki M, Tsuruo T, Ezaki K, Hirano M. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia 1994; 8: 1492-1497.
4. Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry 1994; 17: 84-93.
5. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherer R, Valent P, Havelec L, Ludwig H, Lechner K. mdr1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708-712.
6. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells. Blood 1992; 79: 473-476.
7. Willman CL. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the southwest oncology group leukemia research program. Semin Hematol 1997; 34 (Suppl. 5): 25-33.
8. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen I-M, Head DR, Appelbaum FR, Willman CL. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323-3329.
9. Broxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Währer DCR, Ossenkoppele GJ, Schuurhuis GJ. Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia. Leukemia 1997; 11: 1110-1118.
10. Broxterman HJ, Sonneveld P, Pieters R, Lankelma J, Eekman CA, Loonen AH, Schoester M, Ossenkoppele GJ, Löwenberg B, Pinedo HM, Schuurhuis GJ. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia 1999; 13: 258-265.
11. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele GJ, Währer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Löwenberg B, Schuurhuis GJ. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 1996; 87: 4809-4816.
12. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-1660.
13. Sikic BI. Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 1997; 34 (Suppl. 5): 40-47.
14. Coley HM, Twentyman PR, Workman P. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol 1998; 38: 4467-4475.
15. Consoli U, Priebe W, Ling Y-H, Mahadevia R, Griffin M, Zhao S, Perez-Soler R, Andreeff M. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood 1996; 88: 633-644.
16. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267-3273.
17. Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M. Garnier-Suillerot A. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol Pharmacol 1996; 49: 532-539.
18. Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol Pharmacol 1998; 53: 141-147.
19. Reiffers J, Huguet F, Stoppa A-M, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi D, Hollard D, Fabères C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996; 10: 389-395.
20. Berman E, Wiernik P, Vogler R, Vélez-Gârcia E, Bartolucci A, Whaley FS. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with acute myeloid leukemia. Cancer 1997; 80: 2181-2185.
21. Müller MR, Lennartz K, Boogen C, Nowrousian MR, Rajewski MF, Seeber S. Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression. Ann Hematol 1992; 65: 206-212.
22. Michieli M, Damiani D, Michelutti A, Candoni A, Masolini P, Scaggiante B, Quadrifoglio F, Baccarani M. Restoring uptake and retention of daunorubicin and idarubicin in P-170 related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica 1994; 79: 500-507.
23. Ross DD, Doyle LA, Yang W, Tong Y, Cornblatt B. Susceptibility of idarubicin, daunorubicin, and their alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol 1995; 50: 1673-1603.
24. Sandor V, Fojo T, Bates SE. Future perspectives for the development of P-glycoprotein modulators. Drug Resist Updates 1998; 1: 190-200.
25. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 1994; 54: 4676-4679.
26. Filipits M, Stranzl T, Pohl G, Suchomel RW, Zöchbauer S, Brunner R, Lechner K, Pirker R. MRP expression in acute myeloid leukemia. An update. Adv Exp Med Biol 1999; 457: 141-150.
27. Legrand O, Simonin G, Perrot J-Y, Zittoun R, Marie J-P. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91: 4480-4488.
28. List AF, Spier CS, Grogan TM, lohnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464-2469.
29. Kuiper CM, Broxterman HJ, Baas F, Schuurhuis GJ, Haisma HJ, Scheffer GL, Lankelma J, Pinedo HM. Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1990; 1: 35-41.
30. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EGE, van der Valk P, Meijer CJLM, Pinedo HM. Overexpression of a M. 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475-1479.
31. Kickhoefer VA, Rajavel KS, Scheffer CL, Dalton WS, Scheper RJ, Rome LH. Vaults are upregulated in multidrug-resistant cancer cell lines. J Biol Chem 1998; 273: 8971-8974.
32. Kickhoefer VA, Vasu SK, Rome LH. Vaults are the answer, what is the question? Trends Cell Biol 1996; 6: 174-178.
33. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geisler K, Lechner K, Pirker R. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998; 91: 1508-1513.
34. Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukemia cells predict a poor response to chemotherapy and reduced survival. Br J Haematol 1998; 103: 1083-1091.
35. Leith CP, Kopecky KJ, Chen I-M, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia. A Southwest Oncology Group Study, Blood 1999; 94: 1086-1099.
36. Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, Scheper RJ, Baccarini M. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol 1999; 104: 328-335.
37. Legrand O, Simonin G, Zittoun R, Marie JP. Lung resistance protein (LRP) gene expression in adult acute leukemia: a critical evaluation by three techniques. Leukemia 1998; 12: 1367-1374.
38. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL. Treatment of refractory and relapsed acute myelogenous leukemia with combination therapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999; 93: 787-795.
39. Cabot MC, Han T-Y, Giuliano AE. The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. FEBS Lett 1998; 431: 185-188.